Analysis of CTCL cell lines reveals important differences between
. Blood smear analysis at the time showed ~20% of cells with deeply convoluted nuclei [5] .
SZ4 cells were obtained from a 66-year-old AfricanAmerican female initially diagnosed with stage IIA MF in 1984, who rapidly progressed and developed lymph node involvement with diffuse architectural effacement (clinical stage IVA 2 ) and erythroderma shortly after in 1985. Blood involvement was diagnosed at that time and cell line was established form a peripheral blood sample. SZ4 and Sez4 cells are derived from the same Sézary patient. Based on the literature search it appears that, inadvertently, at some point the name of this cell line has changed from SZ4 to Sez4 [6, 7] , thus, creating some confusion in the field.
Hut78 cells were obtained from peripheral blood of a 53-year-old Caucasian male with Sézary Syndrome involving "skin, blood, lymph nodes and liver." H9 cell line is a clone of Hut78 that was selected for permissiveness of HIV-1 replication, and has been used to isolate and propagate HIV-1 from the blood of patients with acquired immunodeficiency syndrome (AIDS) [8] .
SeAx cells were derived from a peripheral blood of a 66-year-old female with a 8-year history of exfoliative erythroderma and palmoplantar keratoderma with a diagnosis of Sézary Syndrome involving the bone marrow. Importantly, no prior MF plaques were reported in this patient. Lymph node biopsy revealed only dermatopathic changes. This cell line requires IL-2 for continuous growth [9] .
MJ and Hut102 cells were isolated from patients, who clinically at the time were diagnosed with "Mycosis Fungoides variant of CTCL", as described in the papers [10, 11] , and were later found to harbor HTLV-1. In these papers it was not stated whether the diagnosis was changed to ATLL. Hut102 cells were established from a lymph node biopsy [10] , while MJ cells were obtained from peripheral blood [10, 11] .
